Categories: Blood diseases, Gastrointestinal diseases

Aliases & Classifications for Dysentery

MalaCards integrated aliases for Dysentery:

Name: Dysentery 12 43 15 17 71
Infectious Diarrhea 12 54 62


External Ids:

Disease Ontology 12 DOID:12384
ICD9CM 34 009.2
MeSH 43 D004403
SNOMED-CT 67 19213003
UMLS 71 C0013369

Summaries for Dysentery

PubMed Health : 62 About infectious diarrhea: Diarrhea is very common: In Germany, for instance, adults get it once a year on average, and it is even more common in children. It is usually caused by viruses, the most common of which are the highly contagious norovirus and rotavirus. Infectious diarrhea can also come from bacteria such as Salmonella or Campylobacter. In normal cases of diarrhea, you can usually just replace the fluids you lose and wait until the infection goes away. But more severe or longer lasting diarrhea needs to be treated because it can lead to the loss of dangerously high levels of fluid and salt, especially in young children and older people.

MalaCards based summary : Dysentery, also known as infectious diarrhea, is related to amebiasis and diarrhea, and has symptoms including diarrhea An important gene associated with Dysentery is ALB (Albumin), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Allograft rejection. The drugs Simethicone and Omeprazole have been mentioned in the context of this disorder. Affiliated tissues include testes, colon and liver, and related phenotypes are cardiovascular system and hematopoietic system

Disease Ontology : 12 An intestinal infectious disease that involves inflammation of the intestines, especially colon, due to chemical irritants, bacteria, protozoa, or parasitic worms, which results in severe diarrhea with passage of mucus and blood.

Wikipedia : 74 Dysentery is a type of gastroenteritis that results in diarrhea with blood. Other symptoms may include... more...

Related Diseases for Dysentery

Diseases related to Dysentery via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 761)
# Related Disease Score Top Affiliating Genes
1 amebiasis 34.0 TNF IL1B CD4 ALB
2 diarrhea 31.7 TTR TNF IL6 IL1B IFNA2 ALB
3 keratoconjunctivitis 31.7 TNF IL6 ALB
4 colitis 31.5 TNF IL6 IL1B CCR6
5 typhoid fever 31.4 TNF IL6 IL1B IL1A CRP CCR6
6 ulcerative colitis 31.1 TNF IL6 IL1B CRP CCR6
7 salmonellosis 31.1 TNF IL6 IL1B CD4 CCR6 ALB
8 scarlet fever 31.0 TNF CRP ALB
9 gastroenteritis 31.0 TNF IL6 IL1B IFNA2 CRP ALB
10 toxic megacolon 30.9 TNF CRP CCR6 ALB
11 irritable bowel syndrome 30.9 TNF IL6 IL1B CRP
12 iron metabolism disease 30.9 TTR TF CRP
13 gastritis 30.8 TNF IL6 IL1B CCR6
14 cystitis 30.8 TNF IL6 IL1A CRP
15 appendicitis 30.8 TNF IL6 IL1B ENO2 CRP ALB
16 intussusception 30.8 IL6 CRP ALB
17 peritonitis 30.8 TNF IL6 IL1B CRP ALB
18 acute diarrhea 30.8 STX2 STX1A ST8SIA2 CD4
19 sleeping sickness 30.8 TF IL6 HP H2AC18
20 meningitis 30.7 TNF IL6 IL1B IL1A CRP ALB
21 paratyphoid fever 30.6 TNF IL1B IL1A CRP CCR6
22 toxic shock syndrome 30.6 TNF IL6 IL1B CRP
23 parotitis 30.6 CRP CD4 ALB
24 pleural empyema 30.6 CRP CD4 ALB
25 brucellosis 30.6 TNF IL6 CRP
26 enthesopathy 30.6 TNF CRP CCR6
27 drug allergy 30.6 CRP CD4 ALB
28 allergic hypersensitivity disease 30.6 TNF H2AC18 CD4 CCR6
29 viral hepatitis 30.6 TNF IL6 IL1B IFNA2 CRP ALB
30 autonomic nervous system disease 30.6 TTR IL6 ALB
31 pneumonia 30.5 TTR TNF IL6 IL1B IL1A CRP
32 intestinal disease 30.5 TNF IL6 IL1B H2AC18 CRP CD4
33 tetanus 30.5 TNF STX1A IL6 IL1B IL1A CRP
34 kidney disease 30.5 TTR TF IL6 HP CRP ALB
35 clostridium difficile colitis 30.5 IL1RAPL2 IL1B CCR6 ALB
36 crohn's colitis 30.5 TNF IL1B CCR6
37 plague 30.5 TNF IL6 IL1B CD4 ALB
38 immunoglobulin alpha deficiency 30.4 HP CD4 CCR6
39 vasculitis 30.4 TNF IL6 IFNA2 CRP
40 abdominal tuberculosis 30.4 TNF CRP CD4 ALB
41 arthritis 30.4 TNF IL6 IL1B IL1A CRP CCR6
42 purpura 30.4 TNF IL6 CRP
43 guillain-barre syndrome 30.4 TNF HP CCR6 ALB
44 duodenal ulcer 30.4 TNF IL6 IL1B
45 iron deficiency anemia 30.4 TNF TF IL6 CRP
46 infective endocarditis 30.4 TNF IL6 CRP
47 silicosis 30.4 TNF IL1B IL1A
48 hepatitis a 30.4 TNF IL1B IFNA2 ALB
49 reactive arthritis 30.4 TNF IL6 IL1B HP CRP CCR6
50 brain edema 30.4 IL6 IL1B CRP ALB

Comorbidity relations with Dysentery via Phenotypic Disease Network (PDN):

Acute Cystitis

Graphical network of the top 20 diseases related to Dysentery:

Diseases related to Dysentery

Symptoms & Phenotypes for Dysentery

UMLS symptoms related to Dysentery:


MGI Mouse Phenotypes related to Dysentery:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.85 ALB CCR6 CRP DCAF8 HP IL1A
2 hematopoietic system MP:0005397 9.7 CCR6 CD4 DCAF8 HP IL1A IL1B
3 immune system MP:0005387 9.4 ALB CCR6 CD4 CRP DCAF8 HP

Drugs & Therapeutics for Dysentery

PubMed Health treatment related to Dysentery: 62

You lose fluids and electrolytes when you have diarrhea , so it is important to replace them. For acute , non-severe diarrhea you usually just need something like tea with sugar and some salted crackers. Foods that are gentle on the stomach is recommended too, such as rice, bananas or rusk bread. Some people also avoid coffee, fruit juices, sodas, alcohol and fatty foods to keep from irritating their bowel even more. Acute , non-severe diarrhea does not require special treatment in adults and teenagers. But it is a good idea for young children and older people, as well as people with more severe diarrhea, to replace fluids and electrolytes by using oral rehydration salts (electrolyte /glucose solutions) from the pharmacy. These are powders containing salts, minerals and glucose that can be dissolved in water. If these solutions are not available (for instance, while traveling) the following ingredients can be stirred into one liter of bottled or boiled water: Five tablespoons of sugar One and a half level tablespoons of salt One glass of packaged orange juice In addition to drinking fluids and using other treatments , foods or dietary supplements that have probiotic microorganisms (probiotics ) in them can help to make the diarrhea go away faster. Depending on how severe the symptoms are and how long they last, other treatments may be considered too: Drugs like loperamide or racecadotril can help to slow down the activity of the bowel and lower the number of times you need to go to the bathroom. Loperamide is not suitable for children under the age of twelve years, and racecadotril is prescription-only for children. Sometimes certain types of yeast tablets (Perenterol) are also recommended. These tablets are thought to help the body get rid of the germs faster and to support natural gut flora. Charcoal tablets dissolved in water can also be taken to relieve diarrhea symptoms. But there is a lack of good-quality research in this area so no conclusions can be drawn about the benefits and harms of these treatment options. Antibiotics are only an option if the infection is bacterial. They can't fight viruses .

Drugs for Dysentery (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Simethicone Approved Phase 4 8050-81-5
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
Sodium citrate Approved, Investigational Phase 4 68-04-2
Piperazine Approved, Vet_approved Phase 4 110-85-0 4837
Mebendazole Approved, Vet_approved Phase 4 31431-39-7 4030
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
Vancomycin Approved Phase 4 1404-90-6 14969 441141
Fidaxomicin Approved Phase 4 873857-62-6
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
12 Antiparasitic Agents Phase 4
13 Cola Phase 4
14 Emollients Phase 4
15 Proton Pump Inhibitors Phase 4
16 Anthelmintics Phase 4
17 Citrate Phase 4
18 Tubulin Modulators Phase 4
19 Piperazine citrate Phase 4
20 Antimitotic Agents Phase 4
21 DMP 777 Phase 4 157341-41-8
22 Acidophilus Phase 4
23 Fluoroquinolones Phase 4
24 Anti-Retroviral Agents Phase 4
25 Amoxicillin-Potassium Clavulanate Combination Phase 4
26 beta-Lactamase Inhibitors Phase 4
Lactulose Approved Phase 2, Phase 3 4618-18-2 11333
Nitazoxanide Approved, Investigational, Vet_approved Phase 3 55981-09-4 41684
Zinc Approved, Investigational Phase 3 7440-66-6 32051
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
32 Antiprotozoal Agents Phase 2, Phase 3
33 Trace Elements Phase 3
34 Nutrients Phase 3
35 Micronutrients Phase 3
36 Vitamins Phase 3
37 Retinol palmitate Phase 3
38 retinol Phase 3
39 Antioxidants Phase 3
40 Protective Agents Phase 3
41 Bifidobacterium Phase 3
42 Analgesics Phase 3
43 Antiemetics Phase 3
44 Emetics Phase 3
45 Epoetin alfa Phase 3 113427-24-0
46 Diphosphonates Phase 3
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
Magnesium oxide Approved Phase 2 1309-48-4 14792
49 Mango Approved Phase 2
Histamine Approved, Investigational Phase 2 51-45-6 774

Interventional clinical trials:

(show top 50) (show all 125)
# Name Status NCT ID Phase Drugs
1 A Randomized, Parallel Group Comparison of Loperamide/Simeticone Caplet, Loperamide/Simeticone Chewable Tablet (IMODIUM® PLUS) and a Probiotic (Saccharomyces Boulardii) in the Treatment of Acute Diarrhea in Adults Completed NCT00807326 Phase 4 Loperamide/simeticone 2 mg/125 mg caplets;Loperamide/simeticone 2 mg/125 mg chewable tablets;Probiotic Saccharomyces boulardii 250 mg capsules
2 The Effect of a Probiotic and/or Prebiotic on the Duration of Diarrhea and Length of Hospital Stay in Children With Acute Diarrhea: Prospective, Double Blind, Randomized Controlled Trial Completed NCT01927094 Phase 4
3 The Effects of Gastric Acid Suppression on the Colonic Microbiome Completed NCT01901276 Phase 4 Omeprazole 40 mg bid
4 Rifaximin in Standard Three-Day Dosing With and Without the Antimotility Drug, Loperamide, in the Treatment of Travelers' Diarrhea Completed NCT00292344 Phase 4 Rifaximin and loperamide
5 Double-Blind, Placebo-Controlled, Randomized, Prospective, Two-Stage, Two-Arm Study to Evaluate the Efficaciousness and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population Completed NCT02385058 Phase 4 Mebendazole;Quinfamide;Placebo
6 Introduction of New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Management of Diarrhoeal Diseases – A Phase IV Surveillance Study Completed NCT00490932 Phase 4 Hypo-osmolar ORS
7 An Open Label Randomised Controlled Trial of Azithromycin Versus Ciprofloxacin for the Treatment of Children Hospitalised With Dysentery in Ho Chi Minh City, Vietnam Recruiting NCT03854929 Phase 4 Ciprofloxacin;Azithromycin
8 A Phase 4 Open Label Study to Assess the Safety and Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in People Living With HIV/AIDS (PLWHA) With Non-Infectious Diarrhea Recruiting NCT04192487 Phase 4 Crofelemer delayed-release tablets 125mg
9 Effect of Lactobacillus Reuteri DSM 17938 to Prevent Antibiotic-associated Diarrhea in Children: Prospective, Multi-center, Randomize, Parallel Group Placebo Controlled Clinical Trial Recruiting NCT02765217 Phase 4 Lactobacillus reuteri DSM 17938;Placebo;Amoxicillin-Clavulanic Acid
10 CSP #596 - Optimal Treatment for Recurrent Clostridium Difficile Infection Active, not recruiting NCT02667418 Phase 4 Fidaxomicin;Vancomycin with Taper/Pulse;Vancomycin
11 A Parallel, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Probiotic Formula in the Prevention of Traveler's Diarrhea Terminated NCT01005849 Phase 4
12 Protocol CHUM 2014-5056: A Randomized, Double Blinded Placebo Controlled Study to Evaluate the Efficacy of Bio-K+® in the Reduction of the Risk of Clostridium Difficile Infection and Antibiotic Associated Diarrhea in Hospitalized Patients Terminated NCT01972932 Phase 4
13 Single Daily Dose Rifaximin vs. Standard Thrice Daily Dosing for the 3-Day Treatment of Travelers' Diarrhea Withdrawn NCT00875875 Phase 4 Rifaximin
14 Can Use of Bismuth Subsalicylate in Clostridium Difficile Patients Decrease the Length of Stay and Time to Resolution of Symptoms Withdrawn NCT03592082 Phase 4 Bismuth Subsalicylate;standard antibiotic therapy
15 A Randomized, Double-blind, Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone Treatment of Overt Hepatic Encephalopathy Unknown status NCT02464124 Phase 2, Phase 3 Nitazoxanide;Lactulose
16 The Effect of Probiotic Supplementation With Lactobacillus GR-1 and RC-14,on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients; a Randomised, Placebo Controlled Trial Unknown status NCT00536848 Phase 2, Phase 3 Metronidazole
17 Randomized Controlled Field Trial of a Probiotics to Assess Its Role in The Prevention of Acute Diarrhoeal Diseases in Children Unknown status NCT00534170 Phase 3
18 Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Entamoeba Histolytica in Children Completed NCT00366730 Phase 3 Nitazoxanide
19 Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Tablets in the Treatment of Diarrhea Caused by Entamoeba Histolytica in Adults and Adolescents Completed NCT00366236 Phase 3 Nitazoxanide
20 A Phase Three, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System Completed NCT00993681 Phase 3
21 Double Blind, Placebo-Controlled Trial Assessing the Efficacy of Rifaximin in Preventing Campylobacteriosis in Subjects Challenged With Campylobacter Jejuni Completed NCT02280044 Phase 2, Phase 3
22 A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy and Safety of Oral Daily Rifamycin SV-MMX® 400 mg b.i.d. vs. Ciprofloxacin 500 mg b.i.d. in the Treatment of Acute Infectious Diarrhoea in Travellers Completed NCT01208922 Phase 3 Rifamycin SV-MMX®;Ciprofloxacin
23 Fermented Milk and Fermented Rice on the Appearance of Respiratory and Gastrointestinal Symptoms Completed NCT01909128 Phase 3
24 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rifamycin SV MMX for the Treatment of Traveler's Diarrhea Completed NCT01142089 Phase 3 Placebo;Rifamycin SV MMX
25 Phase 3 Study (Safety, Immunogenicity and Efficacy) of Improved Shigella Conjugate Vaccines in 1-4 Year Olds in Israel Completed NCT00368316 Phase 3
26 Effect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following recoveryEffect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following Recovery Completed NCT00321126 Phase 3 Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.
27 Vitamin A Supplementation in Newborns Study Completed NCT00114868 Phase 3 Vitamin A
28 Prevention of Irinotecan Induced Diarrhea by Probiotics: A Phase III Study Recruiting NCT02819960 Phase 3 PROBIO-FIX INUM®;Placebo
29 An Open-label Study to Assess the Safety, Efficacy and Absorption of Exodif™ (Tolevamer Potassium Sodium) Tablets in Patients With Clostridium Difficile-Associated Diarrhea Terminated NCT00466635 Phase 3 GT267-004 (tolevamer potassium sodium)
30 A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center, Therapeutic Equivalence Study to Compare Rifaximin 200 mg Tablets (Sandoz GmbH) to Xifaxan® 200 mg Tablets (Salix Pharmaceuticals, Inc.) and Placebo in Patients With Travelers' Diarrhea Terminated NCT02920242 Phase 3 Rifaximin (Sandoz GmbH) tablet;Rifaximin (Xifaxan);Placebo
31 Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea Withdrawn NCT02736539 Phase 3 CBS 2004 (galacto-oligosaccharides);Placebo
32 A Randomized, Non-inferiority, Active Controlled Clinical Trial to Evaluate the Safety and Efficacy of Ciprofloxacin Versus Doxycycline in the Treatment of Plague in Humans Unknown status NCT01243437 Phase 2 ciprofloxacin;doxyxcycline
33 Probiotics for Infectious Diarrhea in Children in South India Completed NCT01130792 Phase 1, Phase 2
34 A Study of the Pharmacokinetics of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea Completed NCT00382304 Phase 2 tolevamer potassium-sodium (GT267-004)
35 A Randomized, Double-Blind Study of GT160-246 Versus Vancomycin in Patients With C. Difficile-Associated Diarrhea Completed NCT00034294 Phase 2 GT160-246
36 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Two Vaccination Regimen With an LT Vaccine Patch in Healthy Adults Completed NCT00751777 Phase 2
37 A Phase Two, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System in Travelers to Asia Completed NCT01040325 Phase 2
38 A Comparative Double Blind Placebo-Controlled Study of Immunogenicity and Safety of Two Doses 10^5 and 10^7 CFU of SC599 Oral Vaccine, a Live Attenuated Shigella Dysenteriae 1 Vaccine Strain in Healthy Human Adult Volunteers Completed NCT00210288 Phase 2
39 Safety, Immunogenicity, and Efficacy Studies of WRSS1, a Live Attenuated Shigella Sonnei Vaccine Candidate, in Healthy Thai Adults Completed NCT01080716 Phase 1, Phase 2
40 Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection Completed NCT00485134 Phase 1, Phase 2
41 A Phase 2a, Observer Blind, Randomized, Controlled, Single Center Study To Evaluate The Safety, Reactogenicity And Immunogenicity Of 2 Doses Of The GVGH 1790GAHB Vaccine Against Shigella Sonnei, Administered Intramuscularly In Adult Subjects From A Country Endemic For Shigellosis Completed NCT02676895 Phase 2
42 Efficacy, Safety and Immunogenicity of GVGH Shigella Sonnei Vaccine (1790GAHB) in a Human Challenge Study of Healthy Non-immune Adults Completed NCT03527173 Phase 2 Placebo
43 Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a Completed NCT02646371 Phase 2
44 Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea. A Pilot, Dose Finding, Double-blind, Randomized, Multicentre Study Completed NCT03447821 Phase 2 400 mg Rifamycin SV dosage;800 mg Rifamycin SV dosage;1200 mg Rifamycin SV dosage
45 Effect of Irvingia Gabonensis Administration on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity Completed NCT02354339 Phase 2
46 Therapeutic Induction of Endogenous Antibiotics for Improved Recovery in Shigellosis Completed NCT00800930 Phase 2
47 Exploratory Study to Evaluate the Effect of L-isoleucine Supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children and in Inducing Innate Immunity Completed NCT01034228 Phase 2
48 Safety and Immunogenicity of a Shigella-Tetravalent Bioconjugate Vaccine: A Phase 1/2 Randomized Controlled and Age Descending Study Including Dose Finding in 9 Month Old Infants Recruiting NCT04056117 Phase 1, Phase 2
49 Phase IIa Randomized, Single-Blinded, Placebo-Controlled Clinical Trial of the Reprofiled Drug Auranofin for GI Protozoa Recruiting NCT02736968 Phase 2 Auranofin
50 Phase 2b Study of the Safety, Immunogenicity, and Efficacy of a Monovalent Synthetic Carbohydrate-based Conjugate Vaccine (SF2a-TT15) for Protection Against Shigella Flexneri 2a Experimental Infection Recruiting NCT04078022 Phase 2

Search NIH Clinical Center for Dysentery

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Scopolamine Hydrobromide

Cochrane evidence based reviews: dysentery

Genetic Tests for Dysentery

Anatomical Context for Dysentery

MalaCards organs/tissues related to Dysentery:

Testes, Colon, Liver, Small Intestine, Neutrophil, Kidney, Skin

Publications for Dysentery

Articles related to Dysentery:

(show top 50) (show all 8235)
# Title Authors PMID Year
Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. 61 54
19028207 2008
Antibiotics for the empirical treatment of acute infectious diarrhea in children. 54 61
17568855 2006
Traditional uses, botany, phytochemistry, pharmacology, separation and analysis technologies of Euonymus alatus (Thunb.) Siebold: A comprehensive review. 61
32423879 2020
Chemical profile and therapeutic potentials of Xylocarpus moluccensis (Lam.) M. Roem.: A literature-based review. 61
32428655 2020
Genus Ziziphus: A comprehensive review on ethnopharmacological, phytochemical and pharmacological properties. 61
32450235 2020
Immunization of mice against alpha, beta, and epsilon toxins of Clostridium perfringens using recombinant rCpa-b-x expressed by Bacillus subtilis. 61
32447084 2020
Death of a neonatal lamb due to Clostridium perfringens type B in New Zealand. 61
31852382 2020
Protective effect of SKB_Gutbiotic against castor oil and E.coli induced diarrhea in laboratory animals. 61
32142870 2020
Phytochemistry and biological properties of isoprenoid flavonoids from Sophora flavescens Ait. 61
32194169 2020
Effect of Rehydration With Normal Saline Versus Ringer Lactate on Serum Sodium Level of Children With Acute Diarrhea and Severe Dehydration: A Randomized Controlled Trial. 61
32562395 2020
The Role of Oral Administration of Immunoglobulin in Managing Diarrheal Illness in Immunocompromised Children. 61
32180169 2020
Guideline Recommendations for Empirical Antimicrobial Therapy: An Appraisal of Research Evidence for Clinical Decision-Making in Ethiopia. 61
32572787 2020
Ethnobotanical study and phytochemical profiling of Heptapleurum hypoleucum leaf extract and evaluation of its antimicrobial activities against diarrhea-causing bacteria. 61
32537731 2020
Yunnan Baiyao diminishes lipopolysaccharide-induced inflammation in osteoclasts. 61
32189353 2020
Novel Non-competitive Type Three Secretion System ATPase Inhibitors Shut Down Shigella Effector Secretion. 61
32567308 2020
Factors defining the stability of poly(lactide-co-glycolide) spheres for the sustained release of a cysteine protease inhibitor. 61
32360548 2020
Increasing the Affinity of an O-Antigen Polysaccharide Binding Site in Shigella flexneri Bacteriophage Sf6 Tailspike Protein. 61
32189378 2020
Chyme Reinfusion in Intestinal Failure Related to Temporary Double Enterostomies and Enteroatmospheric Fistulas. 61
32403450 2020
Mechanisms of bacillary dysentery: lessons learnt from infant rabbits. 61
31570038 2020
Prevalence of Eleven Infectious Viruses Causing Diarrhea in Korea. 61
32475874 2020
Intestinal Protozoan Parasitic Infections in Immunocompromised Child Patients with Diarrhea. 61
31875601 2020
Lactobacillus plantarum-12 Exopolysaccharides Have Anti-Biofilm Activity Against Shigella flexneri. 61
32444475 2020
Maternal Diarrhea and Antibiotic Use are Associated with Increased Risk of Diarrhea among HIV-Exposed, Uninfected Infants in Kenya. 61
32100682 2020
Daily Temperature and Bacillary Dysentery: Estimated Effects, Attributable Risks, and Future Disease Burden in 316 Chinese Cities. 61
32452706 2020
Metabolic profile of alkaloids in Rhizoma Coptidis in rat plasma, urine and feces after oral administration using ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. 61
32077179 2020
Ethnopharmacology of Hypericum species in China: A comprehensive review on ethnobotany, phytochemistry and pharmacology. 61
32101776 2020
Sanhuang Shu'ai decoction alleviates DSS-induced ulcerative colitis via regulation of gut microbiota, inflammatory mediators and cytokines. 61
32058214 2020
The forgotten tale of Brazilian phage therapy. 61
32213334 2020
Indian Sarsaparilla (Hemidesmus indicus): Recent progress in research on ethnobotany, phytochemistry and pharmacology. 61
32007632 2020
High rate of resistance to ceftriaxone and azithromycin among Shigella spp. isolates at three children's referral hospitals in Northeast Iran. 61
32446727 2020
The antibacterial activity of Berberis heteropoda Schrenk and its effect on irritable bowel syndrome in rats. 61
32451093 2020
Global Transmission, Spatial Segregation, and Recombination Determine the Long-Term Evolution and Epidemiology of Bovine Coronaviruses. 61
32414076 2020
Isolated involvement of corpus callosum in metronidazole-induced encephalopathy with concomitant peripheral neuropathy: A case report. 61
32443341 2020
A Phytochemical and Ethnopharmacological Recapitulation on Hamelia patens. 61
32227313 2020
Pathogen-specific risk of seizure in children with moderate-to-severe diarrhoea: Case control study with follow-up. 61
32428974 2020
Differential expression of hemolysin genes in weakly and strongly hemolytic Brachyspira hyodysenteriae strains. 61
32471432 2020
Impact of climate change on dysentery: Scientific evidences, uncertainty, modeling and projections. 61
31981871 2020
Zinc prevents intestinal epithelial barrier dysfunction induced by alpha-hemolysin-producing Escherichia coli 536 infection in porcine colon. 61
32273011 2020
Ziziphus mucronata Willd. (Rhamnaceae): it's botany, toxicity, phytochemistry and pharmacological activities. 61
32322712 2020
The Antiactivator of Type III Secretion, OspD1, Is Transcriptionally Regulated by VirB and H-NS from Remote Sequences in Shigella flexneri. 61
32123035 2020
Complete genome sequence and annotation of the laboratory reference strain Shigella flexneri serotype 5a M90T and genome-wide transcriptional start site determination. 61
32252626 2020
[Epidemiological analysis on bud-events of Norovirus-associated infectious diarrhea in Shanghai, 2018]. 61
32344480 2020
Diarrhea in kidney transplant recipients: Etiology and outcome. 61
32350724 2020
Socioeconomic factors and bacillary dysentery risk in Jiangsu Province, China: a spatial investigation using Bayesian hierarchical models. 61
32268797 2020
Campylobacter gastroenteritis in children in north-eastern Israel comparison with other common pathogens. 61
32242070 2020
Plagues, pandemics and epidemics in Irish history prior to COVID-19 (coronavirus): what can we learn? 61
32404230 2020
Chronic high-level multidrug-resistant Campylobacter coli enterocolitis in an agammaglobulinemia patient: Oral gentamicin efficacy. 61
32353415 2020
Andrographolide potentiates PD-1 blockade immunotherapy by inhibiting COX2-mediated PGE2 release. 61
32018066 2020
Towards capture of dynamic assembly and action of the T3SS at near atomic resolution. 61
31821956 2020
Transcytosis subversion by M cell-to-enterocyte spread promotes Shigella flexneri and Listeria monocytogenes  intracellular bacterial dissemination. 61
32282860 2020

Variations for Dysentery

Expression for Dysentery

Search GEO for disease gene expression data for Dysentery.

Pathways for Dysentery

Pathways related to Dysentery according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
12.58 TNF IL6 IL1B IL1A CD4
Show member pathways
12.57 TNF IL6 IL1B IL1A CD4
Show member pathways
Show member pathways
8 12.22 TNF IL6 IL1B IFNA2
9 12.13 TNF IL6 IL1B IL1A IFNA2
Show member pathways
12.09 TNF IL1B IL1A IFNA2 H2AC18
11 12.01 TNF TF IL6 IL1B IL1A
12 11.99 TNF IL6 IL1B IL1A
13 11.96 TNF IL6 IFNA2 CD4
14 11.93 TNF IL6 IL1B IL1A
Show member pathways
11.89 TNF IL6 IL1B CD4
16 11.86 TNF IL6 IL1B IL1A
17 11.82 TNF IL6 IL1B IL1A
18 11.71 TNF IL1B CD4 CCR6
19 11.68 TNF IL6 IL1B IL1A
20 11.65 TNF IL6 IL1B
21 11.59 TNF IL6 IL1B
22 11.55 TNF IL6 IL1B IL1A CD4
23 11.53 TNF IL6 IL1B
Show member pathways
11.53 TNF IL6 IL1B IL1A
25 11.51 IL6 IL1B IL1A
26 11.5 TNF IL6 HP
Show member pathways
11.44 TNF STX1A IL1B
28 11.37 TNF IL6 IL1B
29 11.36 TNF IL6 IL1B IL1A
30 11.34 IL6 IL1B IL1A
31 11.29 TNF IL6 IL1B
32 11.28 TNF IL6 IL1B IL1A
33 11.27 TNF IL6 IL1B
34 11.22 TNF IL6 IL1B IFNA2 CD4
35 11.1 TNF IL6 IL1B IL1A
36 10.98 TNF IL6 CRP
37 10.51 IL1B IL1A
38 10.48 TNF IL6 IL1B IL1A CD4

GO Terms for Dysentery

Cellular components related to Dysentery according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 TTR TNF TF STX1A IL6 IL1B
2 extracellular space GO:0005615 9.4 TTR TNF TF STX2 IL6 IL1B

Biological processes related to Dysentery according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 10.05 TNF TF IL6 IL1B IFNA2 CD4
2 positive regulation of gene expression GO:0010628 10.04 TNF IL6 IL1B IL1A CRP
3 immune response GO:0006955 9.95 TNF IL6 IL1B IL1A CD4 CCR6
4 cellular protein metabolic process GO:0044267 9.94 TTR TF IL6 ALB
5 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.91 TNF IL1B IL1A CD4
6 cellular response to lipopolysaccharide GO:0071222 9.89 TNF IL6 IL1B IL1A
7 inflammatory response GO:0006954 9.85 TNF IL6 IL1B IL1A IFNA2 CRP
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.81 TNF IL6 IFNA2
9 regulation of insulin secretion GO:0050796 9.8 TNF STX1A IL1B
10 positive regulation of T cell proliferation GO:0042102 9.79 IL6 IL1B CD4
11 positive regulation of interleukin-6 production GO:0032755 9.77 TNF IL6 IL1B
12 positive regulation of interleukin-6 secretion GO:2000778 9.74 TNF IL1B IL1A
13 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.71 TNF IL1B IL1A
14 acute-phase response GO:0006953 9.7 IL6 HP CRP
15 positive regulation of vascular endothelial growth factor production GO:0010575 9.63 IL6 IL1B IL1A
16 regulation of establishment of endothelial barrier GO:1903140 9.62 TNF IL1B
17 ectopic germ cell programmed cell death GO:0035234 9.61 IL1B IL1A
18 negative regulation of neurogenesis GO:0050768 9.61 TNF IL6 IL1B
19 positive regulation of fever generation GO:0031622 9.58 TNF IL1B
20 positive regulation of glial cell proliferation GO:0060252 9.58 TNF IL6 IL1B
21 positive regulation of immature T cell proliferation in thymus GO:0033092 9.56 IL1B IL1A
22 humoral immune response GO:0006959 9.56 TNF IL6 IFNA2 CCR6
23 sequestering of triglyceride GO:0030730 9.55 TNF IL1B
24 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.51 TNF IL1B
25 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.5 IL1B IL1A CD4
26 fever generation GO:0001660 9.49 IL1B IL1A
27 positive regulation of neuroinflammatory response GO:0150078 9.33 TNF IL6 IL1B
28 cytokine-mediated signaling pathway GO:0019221 9.23 TNF STX1A IL6 IL1RAPL2 IL1B IL1A
29 negative regulation of lipid storage GO:0010888 9.13 TNF IL6 CRP

Molecular functions related to Dysentery according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 TTR TNF TMPO TF STX2 STX1A
2 cytokine activity GO:0005125 9.02 TNF IL6 IL1B IL1A IFNA2

Sources for Dysentery

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....